First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
Clinical trial NCT04350736 · COMPLETED
Trial details
- NCT number
- NCT04350736
- Sponsor
- Theravance Biopharma
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-23
- Primary completion
- 2020-06-24
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.